MPR Weekly Dose

This week we have news of two new approval for atopic dermatitis; Warnings around counterfeit HIV treatments; Zydelig indications withdrawn; CDC pediatric influenza vaccine study results; And an FDA warning against a particular brand of COVID-19 antibody tests.

This week: Novel insomnia treatment; The FDA comment on magnesium hypertension claim; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycle in relation to COVID vaccines; And experts have their say on the best diets for 2022.

Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis. 

This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and imp...

We made it to 100! This week Pfizer seeks Emergency Use Authorization for their COVID oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treat...

This week there's positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate. 

The FDA votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.

This week: big news announced in COVID-19, with the FDA stating that mixing and matching of vaccines for the booster dose is authorized. The first interchangeable biosimilar to Humira is approved. Also there's approvals for dry eye disease, pain management and opioid overdoses. 

This week the USPSTF update aspirin recommendations for those 60 years and older; The FDA take a stance on needle-free devices for injecting dermal fillers; REMS requirements are updated for isotretinoin products; A new treatment approved for pediatric congenital athymia; An emergency use request submitted for an oral antiviral COVID treatment; And the FDA advisory panel vote on boosters for the M...

Dr Preeti Malani, Chief Health Officer at UM, joined us to talk about the current state of the COVID-19 pandemic, including vaccine hesitancy, mandates, boosters and how the future may unfold.

The Pfizer-BioNTech vaccine gets Emergency Use Authorization for booster dose in certain individuals; A smaller dose appears safe and effective in children; Janssen share booster data for their vaccine; A survey sheds light on parents' thoughts on child COVID vaccination; Remdesivir efficacy data in COVID-19 patients, And Opzelura is approved for atopic dermatitis.

This week the FDA weigh up mandatory education for opioid prescribers; There's an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approvals for lymphoma and NSCLC, respectively; And a number of supplement companies received FDA warning letters. 

This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There's new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.

The first COVID-19 vaccine is fully approved by the FDA, we'll go into all that that entails and also news regarding booster doses, off-label recommendations, promising antibody treatments and a BLA submission from Moderna for their vaccine.

This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval. 

Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication.

The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay'd for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn. 

This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there's a new treatment approved for Progressive Familial Intrahepatic Cholestasis (PFIC).

This week on the pod we speak about a fact sheet update for the Janssen COVID vaccine. Pfizer and BioNTech are working on a booster version of their vaccine. A supplement is found to contain a prescription ingredient. There's a new treatment for patients with diabetic kidney disease. And two popular sunscreen brands are recalled due to the presence of benzene.

This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there's updates to the cancer drug Keytruda.

The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. R evisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new d...

This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published. 

This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax's vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers.

This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We'll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12.

On this week's show we have news of migraine prevention treatment, a hexavalent vaccine is approved for pediatrics, there's also an approval for schizophrenia and bipolar I disorder, lumakras gets fast tracked and there's a new diagnostic aid for Autism, and it is artificial intelligence.